Adial Pharmaceuticals (ADIL) to Release Quarterly Earnings on Wednesday

Adial Pharmaceuticals (NASDAQ:ADIL) is projected to issue its results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.

Adial Pharmaceuticals (NASDAQ:ADIL) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. On average, analysts expect Adial Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adial Pharmaceuticals Price Performance

Shares of Adial Pharmaceuticals stock opened at $0.33 on Monday. The stock has a market cap of $7.11 million, a price-to-earnings ratio of -0.31 and a beta of 1.32. The firm’s 50-day moving average is $0.36 and its two-hundred day moving average is $0.44. Adial Pharmaceuticals has a 1 year low of $0.22 and a 1 year high of $1.30.

Analysts Set New Price Targets

ADIL has been the topic of a number of recent research reports. Maxim Group upgraded Adial Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research report on Tuesday, September 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Adial Pharmaceuticals to a “sell” rating in a research note on Saturday, July 26th. Finally, Zacks Research cut shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 20th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $4.75.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.